Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $125.1 million.

  • Avalo Therapeutics' Liabilities and Shareholders Equity rose 2706.31% to $125.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.9 million, marking a year-over-year increase of 5390.16%. This contributed to the annual value of $150.7 million for FY2024, which is 61801.08% up from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' Liabilities and Shareholders Equity is $125.1 million, which was up 2706.31% from $126.6 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Liabilities and Shareholders Equity ranged from a high of $150.7 million in Q4 2024 and a low of $21.0 million during Q4 2023
  • Over the past 5 years, Avalo Therapeutics' median Liabilities and Shareholders Equity value was $64.1 million (recorded in 2021), while the average stood at $76.3 million.
  • As far as peak fluctuations go, Avalo Therapeutics' Liabilities and Shareholders Equity plummeted by 6167.31% in 2022, and later surged by 61801.08% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Liabilities and Shareholders Equity stood at $80.2 million in 2021, then crashed by 58.4% to $33.4 million in 2022, then crashed by 37.08% to $21.0 million in 2023, then surged by 618.01% to $150.7 million in 2024, then dropped by 17.01% to $125.1 million in 2025.
  • Its last three reported values are $125.1 million in Q3 2025, $126.6 million for Q2 2025, and $138.5 million during Q1 2025.